BRIEF published on 12/09/2025 at 18:35, 4 months 27 days ago Theraclion submits Sonovein to the FDA after significant progress FDA Theraclion SONOVEIN Varicose Veins HIFU
BRIEF published on 12/09/2025 at 18:35, 4 months 27 days ago Theraclion Submits Sonovein to FDA After Year of Key Achievements FDA Submission Clinical Evidence SONOVEIN Regulatory Achievements Varicose Vein Treatment
PRESS RELEASE published on 12/09/2025 at 18:30, 4 months 27 days ago Inside Information / Other news releases Theraclion announces FDA submission of Sonovein following a year of regulatory and clinical achievements. Key milestones in Europe and China also reached Clinical Milestones FDA Submission Theraclion SONOVEIN Regulatory Achievements
BRIEF published on 10/29/2025 at 18:35, 6 months 7 days ago Theraclion Announces 2025 Half-Year Financial Results and Strategic Progress Financial Results Revenue Growth Market Expansion U.S. Study Certification Progress
PRESS RELEASE published on 10/29/2025 at 18:30, 6 months 7 days ago Inside Information / News release on accounts, results Theraclion reports successful pivotal study, CE certification, GB 9706.1-2020 certification; 89% revenue increase and 23% operating loss reduction in 2025 half-year results Revenue Increase Operating Loss Reduction CE Certification Pivotal Study Theraclion
BRIEF published on 10/21/2025 at 18:35, 6 months 15 days ago Theraclion obtains crucial certification in China Medical Theraclion SONOVEIN® Focused Ultrasound Chinese Certification
BRIEF published on 10/10/2025 at 18:35, 6 months 26 days ago Monthly publication of Theraclion voting rights Share Capital Voting Rights Investment Euronext Growth Theraclion
PRESS RELEASE published on 10/10/2025 at 18:30, 6 months 26 days ago Inside Information / Other news releases Theraclion provides monthly update on total voting rights and shares. The French MedTech company uses focused ultrasound for non-invasive treatment. CE-marked platform SONOVEIN® targets varicose veins Voting Rights Shares Theraclion SONOVEIN Focused Ultrasound
BRIEF published on 09/15/2025 at 18:35, 7 months 20 days ago Theraclion Successfully Completes Pivotal Study with 96.8% Occlusion Rate FDA Clinical Trial Theraclion SONOVEIN® Varicose Veins
PRESS RELEASE published on 09/15/2025 at 18:30, 7 months 20 days ago Inside Information / Other news releases Theraclion announces successful U.S. FDA pivotal study showing 96.8% occlusion rate with Sonovein® for varicose vein treatment. Results support potential U.S. market entry Theraclion SONOVEIN® U.S. FDA Study Varicose Vein Treatment Occlusion Rate
Published on 05/06/2026 at 02:00, 14 minutes ago Vanta Announces Closing of First Tranche of Private Placement and Debt Settlement
Published on 05/06/2026 at 00:20, 1 hour 54 minutes ago Hillcrest Energy Technologies Announces Adoption of Semi-Annual Reporting
Published on 05/06/2026 at 01:35, 38 minutes ago VERNAL CAPITAL ACQUISITION CORP. ANNOUNCES PRICING OF $100 MILLION INITIAL PUBLIC OFFERING
Published on 05/06/2026 at 00:05, 2 hours 8 minutes ago ESOC 2026: Rising stroke rates highlight widening ethnic and socioeconomic inequalities across populations, major study finds
Published on 05/05/2026 at 23:05, 3 hours 8 minutes ago Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
Published on 05/05/2026 at 22:07, 4 hours 7 minutes ago Kaufman & Broad SA: DIVIDEND PAYMENT IN RESPECT OF THE FINANCIAL YEAR ENDED NOVEMBER 30, 2025
Published on 05/05/2026 at 21:56, 4 hours 17 minutes ago Kaufman & Broad SA: DESCRIPTION OF THE SHARE REPURCHASE PROGRAM OF 2026, MAY 5
Published on 05/05/2026 at 19:00, 7 hours 14 minutes ago Combined General Meeting of Air Liquide Shareholders of May 5, 2026
Published on 05/05/2026 at 18:03, 8 hours 10 minutes ago Aéroports de Paris SA - Shares and voting rights as of 30 April 2026
Published on 05/05/2026 at 17:53, 8 hours 20 minutes ago TF1 - Monthly disclosure of the total number of shares and voting rights - April 2026
